Vertex Pharmaceuticals (NASDAQ:VRTX) Announces Earnings Results

Vertex Pharmaceuticals (NASDAQ:VRTX) issued its quarterly earnings results on Monday. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06), FiscalAI reports. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Third-quarter revenue rose 12% year over year, and Vertex raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion, reflecting continued CF performance and growing contributions from CASGEVY, JOURNAVX, and PALSONIFY.
• Commercial momentum remained strong across newer products: ALYFTREK generated $706 million in quarterly sales, CASGEVY revenue increased 30% sequentially to $99 million, JOURNAVX prescriptions surpassed 750,000, and PALSONIFY reached $10 million in September.
• Vertex is preparing for the November 30 FDA decision on povetacicept in IgA nephropathy, highlighting its expected efficacy, tolerability, and once-monthly at-home auto-injector; the company also completed enrollment in the pivotal AMPLITUDE study of inaxaplin and expects interim data in early 2027.
• The company advanced its pipeline by prioritizing VX-017, an allogeneic, off-the-shelf islet cell therapy for type 1 diabetes, with phase I/II dosing underway and a goal of entering pivotal development next year; it also reported encouraging early results for the VX-828 next-generation CF corrector.
• Vertex increased full-year non-GAAP operating expense guidance to approximately $6 billion, including Crinetics-related costs, and incurred roughly $50 million in third-quarter financing and transaction costs; the Crinetics acquisition also added $4.5 billion in term loans at approximately 4.8% interest.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded down $5.73 during trading on Monday, hitting $553.15. 3,051,501 shares of the company traded hands, compared to its average volume of 1,388,979. The business’s fifty day moving average is $523.21 and its 200 day moving average is $479.47. Vertex Pharmaceuticals has a fifty-two week low of $403.16 and a fifty-two week high of $568.67. The firm has a market capitalization of $140.39 billion, a price-to-earnings ratio of 32.20, a P/E/G ratio of 2.68 and a beta of 0.28.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue growth and raised guidance support the outlook. Vertex reported third-quarter revenue of $3.44 billion, above the $3.42 billion analyst consensus, citing growth across its increasingly diversified portfolio. The company also raised its full-year 2026 revenue guidance, a positive signal for investors. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Alyftrek continues to expand the cystic fibrosis franchise. The transition from Trikafta to Alyftrek remains a key growth driver, while Vertex also highlighted continued progress in its research pipeline and the successful completion of the Crinetics acquisition. Vertex Spends Its CF Growth on New Launches
• Neutral Sentiment: Investors are also weighing recent kidney-disease data. Phase 3 data for povetacicept provided a potential pipeline catalyst, although the stock’s previous gains and elevated valuation raise questions about how much future success is already reflected in the share price. Is Vertex Pharmaceuticals Fully Priced Following Its Kidney Data Update?
• Negative Sentiment: Quarterly profit fell short of expectations. Adjusted earnings were $4.76 per share versus the Zacks consensus estimate of $4.92 and $4.80 a year earlier. Higher investment in new launches and the Crinetics deal limited earnings growth despite the revenue beat. Vertex Pharmaceuticals Misses Q3 Earnings Estimates

Analysts Set New Price Targets

VRTX has been the topic of several research analyst reports. Canaccord Genuity Group upped their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research report on Tuesday, August 4th. Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Morgan Stanley started coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $665.00 price target on the stock. Finally, UBS Group increased their price target on Vertex Pharmaceuticals from $585.00 to $615.00 and gave the stock a “buy” rating in a report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $579.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.